Radiotracers for different angiogenesis receptors in a melanoma model

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 45-53

  Oliveira, Érica A ^a   Faintuch, Bluma L ^a   Núñez, Eutímio Gustavo F ^a   Maria Moro, Ana ^b   Nanda, Prasant K ^c   Smith, Charles J ^c  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c University of Missouri   (United States)

Author keywords

angiogenesis; melanoma; RGD and NGR peptides; technetium 99m

Indexed keywords

ANTIMONY TARTRATE; MERTIATIDE TC 99M; PENTAPEPTIDE; TECHNETIUM 99M;

ANGIOGENESIS; ARTICLE; CELL LINE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RADIOCHEMISTRY; URINARY EXCRETION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYVINYLS; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; TECHNETIUM; TECHNETIUM COMPOUNDS;

EID: 84855784595     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834e6a7e     Document Type: Article

References (39)

1. Brown KC. Peptidic tumor targeting agents: The road from phage display peptide selections to clinical applications. Curr Pharm Des 2010; 16: 1040-1054.
2. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380. (Pubitemid 28063372)
3. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-565. (Pubitemid 38297190)
4. Kumar CC. Integrin avb3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003; 4:123-131. (Pubitemid 36553584)
5. Liu S, Robinson SP, Edwards DS. Radiolabeled integrin avb3 antagonists as radiopharmaceuticals for tumor radiotherapy. Top Curr Chem 2005; 252:117-153.
6. Haubner R, Wester HR. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004; 10:1439-1455. (Pubitemid 38559759)
7. Chen X. Multimodality imaging of tumor integrin avb3 expression. Mini-Rev Med Chem 2006; 6:227-234.
8. Cai W, Gambhi S, Chen X. Multimodality tumor imaging targeting integrin avb3. BioTechniques 2005; 39:S6-S17.
9. Dobrucki LW, Sinusa AJ. Imaging angiogenesis. Curr Opin Biotechnol 20 7; 18:90-96.
10. Warren BA, Shubik P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 1966; 15:464-478.
11. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62:867-874. (Pubitemid 34126966)
12. Van Hensbergen Y, Broxterman HJ, Rana S, Van Diest PJ, Duyndam MC, Hoekman K, et al. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res 2004; 10:1180-1191. (Pubitemid 38198920)
13. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60:722-727. (Pubitemid 30094573)
14. Fontijn D, Duyndam MC, Van Berkel MP, Yuana Y, Shapiro LH, Pinedo HM, et al. CD13/aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells. Br J Cancer 2006; 94:1627-1636. (Pubitemid 43924925)
15. Arap W, Kolonin MG, Trepel M, Lahdenrant J, Cardó -Vila M, Giordano RJ, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8:121-127. (Pubitemid 34155122)
16. Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, Bachi A, et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 2006; 281:36466-36476. (Pubitemid 46041380)
17. Netscher DT, Leong M, Orengo I, Yang D, Berg C, Krishnan B. Cutaneous malignancies: Melanoma and nonmelanoma types. Plast Reconstr Surg 2011; 127:37e-56e.
18. Chen X, Park R, Sharinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004; 31:11-19. (Pubitemid 38115121)
19. Chen X, Park R, Sharinian AH, Tohme M, Khankaldyan V, Bozorgzadeh MH, et al. 18F-labebled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004; 31:179-189. (Pubitemid 38315112)
20. Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol I 2008; 35: 1507-1515.
21. Dijkgraaf I, Kruijtzer AW, Liu S, Soede AC, Oyen WJG, Corstens FHM, et al. Improved targeting of the alpha(v)beta(3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol I 2007; 34:267-273. (Pubitemid 46147510)
22. Liu S, Kim YS, Hsieh WY, Sreerama SG. Coligant effect on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramer. Nucl Med Bio 2008; 35:111-121. (Pubitemid 350298246)
23. Wu Y, Zhang XZ, Xiong ZM, Cheng Z, Fisher DR, Liu S. MicroPET imaging of glioma av-integrin expression using 64Cu labeled tetrametric RGD peptide. J Nucl Med 2005; 56:1707-1718.
24. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009; 52:425-432.
25. Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X. A new (18)F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 2011; 41:439-447.
26. Rofstad EK, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia 2010; 12:889-898.
27. Kim J, Hong SY, Park HS, Kim DS, Lee W. Structure and function of RGD peptides derived from disintegrin proteins. Mol Cells 2005; 19:205-211.
28. Kostidis S, Stavrakoudis A, Biris N, Tsoukatos D, Sakarellos C, Tsikaris V. The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides. J Pept Sci 2004; 10:494-509. (Pubitemid 39162383)
29. Verrier S, Pallu S, Bareille R, Jonczyk A, Meyer J, Dard M, et al. Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process. Biomaterials 2002; 23:585-596. (Pubitemid 33054066)
30. Metaferia BB, Rittler M, Gheeya JS, Lee A, Hempel H, Plaza A, et al. Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry. Bioorg Med Chem Lett 2010; 20:7337-7340.
31. Banerjee SR, Maresca KP, Francesconi L, Valliant J, Babich JW, Zubieta J. New directions in the coordination chemistry of 99mTc: A reflection on technetium core structures and a strategy for new chelate design. Nucl Med Biol 2005; 32:1-20.
32. Winnard P Jr., Chang F, Ruschowski M, Mardirossian G, Hnatowich DJ. Preparation and use of NHS-MAG3 for technetium-99m labeling DNA. Nucl Med Biol 1997; 24:425-432. (Pubitemid 27359620)
33. Lister-James J, Moyer BR, Dean RT. Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 1997; 41:111-118. (Pubitemid 27261309)
34. Stevenson D, Miller S, Wilson ID. Extraction methods in organic analysis. 1st ed. Sheffield: Sheffield Academic Press; 2000.
35. Stevenson D, Wilson ID. Sample preparation for biomedical and environmental analysis. 1st ed. New York: Plenum; 1994.
36. Svensson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice: rationale and current status. Clin Pharmacokinet 1986; 11:450-460.
37. Sancey L, Ardisson V, Riou LM, Ahmadi M, Marti-Batlle D, Boturyn D, et al. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta(3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol I 2007; 34:2037-2047. (Pubitemid 350212119)
38. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M,Wester HJ. Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin 2004; 43:26-32. (Pubitemid 38233141)
39. Decristoforo C, Faintuch BL, Rey A, Guggenberg E, von, Rupprich M, Hernandez IG, et al. [99mTc] HYNIC-RGD for imaging integrin avb3 expression. Nucl Med Biol 2006; 33:945-952.